Vanguard Portfolio Management LLC Discloses New 5.56% Stake in Ligand Pharmaceuticals Inc

Vanguard Portfolio Management LLC filed a Schedule 13G on May 1, 2026, disclosing a new ownership stake in Ligand Pharmaceuticals Inc (LGND). As of the event date on March 31, 2026, the firm reported beneficial ownership of 1,109,154 shares of common stock, representing 5.56% of the company. The filing indicates that Vanguard Portfolio Management exercises sole dispositive power over the entire holding of 1,109,154 shares, while holding sole voting power over 8,887 shares. This position includes securities held by Vanguard funds and affiliates, including Vanguard Fiduciary Trust Company and Vanguard Global Advisers, LLC. The filing was made under Rule 13d-1(b), certifying that the shares were acquired in the ordinary course of business and not for the purpose of changing or influencing the control of the issuer. This represents a significant new position for the investment adviser, crossing the 5% regulatory disclosure threshold.